ViennaLab - PGX-5FU XL StripAssay®

Fluoropyrimidines are widely used for the treatment of various solid tumors. The PGX-5FU XL StripAssay^® covers the four most clinically relevant variants in the dihydropyrimidine dehydrogenase (DPYD) gene with therapeutic relevance for fluoropyrimidine treatment as recommended by the European Medicines Agency in April 2020.

PGX-5FU XL

• Fluoropyrimidines (5-Fluorouracil, Capecitabine and Tegafur) are frequently used in cancer therapy. However, some patients develop severe treatment-related toxicity.
• A part of fluoropyrimidine-related toxicity arises due to impaired activity of the key metabolic enzyme dihydropyrimidine dehydrogenase (DPD) caused by genetic variants in the DPYD gene.
• CPIC Guidelines recommend DPYD genotype-guided fluoropyrimidine dosing to increase patient safety.